• Neurocrine began a Phase 1 first-in-human study of NBIP-'1968, a long-acting GLP-1/GIP/glucagon receptor triple agonist for obesity.
• Initial Phase 1 work tests single ascending doses in adults across BMI categories, including overweight and obese, focusing on safety and tolerability.
• Program targets once-weekly subcutaneous dosing; designed with balanced glucagon activity to improve metabolic benefit while supporting tolerability.
• NBIP-'1968 is intended for fixed-dose combination with NBIP-'2118, a separate obesity candidate already in Phase 1 development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608070830PR_NEWS_USPR_____LA21218) on August 07, 2026, and is solely responsible for the information contained therein.